SUPN

Nov 09, 2:00 PMBank of America initiates coverage of Supernus with a ‘buy’ rating and $47 price target, citing undervaluation and enhanced growth from the Indivior merger.

Peers: ALKS NBIX ACAD AXSM COLL HRMY INDV JAZZ AMRX BIIB

| Held by: IJR IWM VTI VB VTI VB VBK SPSM IJT VXF

Scroll to Statements

Index	RUT
Market Cap	5.75B
Enterprise Value	5.94B
Income	450.00M
Sales	1.37B
Book/sh	-0.51
Cash/sh	1.47
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Nov 03, 2026
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	838
IPO	May 01, 2012

P/E	7.66
Forward P/E	6.81
PEG	0.30
P/S	4.18
P/B	-
P/C	18.84
P/FCF	221.31
EV/EBITDA	9.39
EV/Sales	4.32
Quick Ratio	0.50
Current Ratio	0.62
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	3.61
EPS next Y	4.06
EPS next Q	0.93
EPS this Y	34.55%
EPS next Y	20.78%
EPS next 5Y	22.42%
EPS past 3/5Y	- -
Sales past 3/5Y	11.20% 13.88%
EPS Y/Y TTM	265.06%
Sales Y/Y TTM	16.44%
EPS Q/Q	244.87%
Sales Q/Q	13.38%
Earnings	Oct 29 BMO
EPS/Sales Surpr.	24.45% 8.09%

Insider Own	3.00%
Insider Trans	0.00%
Inst Own	96.58%
Inst Trans	-4.51%
ROA	32.75%
ROE	-
ROIC	-
Gross Margin	85.08%
Oper. Margin	45.05%
Profit Margin	32.75%
SMA20	2.36%
SMA50	1.37%
SMA200	-0.29%
Trades

Shs Outstand	124.77M
Shs Float	121.03M
Short Float	3.34%
Short Ratio	1.24
Short Interest	4.04M
52W High	33.22 -16.73%
52W Low	21.48 28.78%
Volatility	8.28% 4.97%
ATR (14)	1.27
RSI (14)	52.65
Beta	-0.57
Rel Volume	0.25
Avg Volume	3.25M
Volume	66,470

Perf Week	-1.75%
Perf Month	-1.15%
Perf Quarter	-7.96%
Perf Half Y	-6.88%
Perf YTD	-0.65%
Perf Year	15.43%
Perf 3Y	123.28%
Perf 5Y	118.02%
Perf 10Y	65.41%
Recom	1.20
Target Price	47.60
Prev Close	27.62
Price	27.66
Change %	0.14%

Consensus

Strong Buy

Avg. Price Target

$47.60

Implied Upside

+72.1%

Analysts9incl. previous ratings

Rating Distribution7 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 09, 2026	Initiated	BBofA Securities	Buy	$47	+69.9%
Nov 04, 2026	Resumed	PPiper Sandler	Overweight	$47	+69.9%
Oct 09, 2025	Upgrade	PPiper Sandler	Neutral → Overweight	$65	+135.0%
Jul 30, 2025	Upgrade	CCantor Fitzgerald	Neutral → Overweight	$42	+51.9%
Feb 19, 2025	Downgrade	CCantor Fitzgerald	Overweight → Neutral	$57 → $36	+30.2%
Jan 06, 2025	Initiated	CCantor Fitzgerald	Overweight	$57	+106.1%
Sep 11, 2024	Downgrade	PPiper Sandler	Overweight → Neutral	$41 → $36	+30.2%
Jan 03, 2023	Resumed	JJefferies	Buy	$44 → $45	+62.7%
Dec 01, 2021	Resumed	JJefferies	Buy	$40 → $44	+59.1%
Apr 13, 2021	Upgrade	JJefferies	Hold → Buy	$25 → $40	+44.6%
Jun 16, 2020	Upgrade	PPiper Sandler	Neutral → Overweight	$25 → $31	+12.1%
Jun 15, 2020	Resumed	JJefferies	Hold	$24	-13.2%
Nov 08, 2019	Downgrade	BBerenberg	Buy → Hold
Nov 07, 2019	Downgrade	SStifel	Buy → Hold	$55 → $23	-16.8%
Nov 06, 2019	Downgrade	JJefferies	Buy → Hold	$46 → $23	-16.8%
Nov 12, 2018	Reiterated	BB. Riley FBR	Buy	$68 → $65	+135.0%
Jan 18, 2018	Reiterated	BB. Riley FBR, Inc.	Buy	$54	+95.2%
Dec 28, 2017	Reiterated	BB. Riley FBR, Inc.	Buy	$50 → $54	+95.2%
Dec 04, 2017	Upgrade	JJanney	Neutral → Buy
Nov 08, 2017	Upgrade	SStifel	Hold → Buy	$47	+69.9%

Today 08:30AM	Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-09-26 01:45PM	Supernus undervalued after Indivior merger, says Bank of America (Proactive) +5.58%
Nov-02-26 09:18AM	Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader (GlobeNewswire)
Oct-29-26 06:38PM	Supernus Ends Its Standalone Era With A Big Beat And Higher Guidance, But The Indivior Merger Now Drives The Story (Earnings Whispers)
04:42PM	Supernus: Q3 Earnings Snapshot (Associated Press)
04:05PM	Loading…
04:05PM	Supernus Announces Third Quarter 2026 Financial Results (GlobeNewswire)
Oct-28-26 05:43PM	Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600 (PR Newswire)
08:30AM	Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree for 'Ms. Represented' Campaign (GlobeNewswire)
Oct-22-26 06:27PM	Huron Consulting stock rises on S&P SmallCap 600 addition (Investing.com)
06:08PM	MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600 (PR Newswire)
06:55AM	Supernus Must Prove Its Standalone Engine Still Hums As Indivior Merger Nears (Earnings Whispers)
Oct-21-26 07:45PM	Supernus Announces Orphan Drug Exclusivity for ONAPGO (apomorphine HCl) (GlobeNewswire)
Oct-19-26 08:30AM	Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026 (GlobeNewswire)
Sep-25-26 07:38AM	Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders? (PR Newswire)
Sep-02-26 04:30PM	Supernus Pharmaceuticals to Participate in September Investor Conferences (GlobeNewswire)
08:30AM	Loading…
Aug-31-26 08:30AM	Chloe Kim Teams Up with Qelbree, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD (GlobeNewswire)
Aug-07-26 05:06PM	Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? (PR Newswire)
Aug-05-26 01:05AM	Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com) +6.11%
Aug-04-26 07:57AM	Supernus and Indivior merge to create scaled, CNS-focused entity (Pharmaceutical Technology)
Aug-03-26 01:41PM	Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders? (PR Newswire) -6.60%
08:28AM	Supernus Shares Jump After Revenue Beat, Higher Guidance and Indivior Merger Announcement (InvestorsHub)
08:22AM	Supernus jumps premarket on merger deal; GameStop drops (Investing.com)
06:47AM	Supernus: Q2 Earnings Snapshot (Associated Press)
06:35AM	Supernus Announces Second Quarter 2026 Financial Results (GlobeNewswire)
06:30AM	Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale (GlobeNewswire)
Jul-22-26 05:05PM	Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026 (GlobeNewswire)
Jul-14-26 08:30AM	Supernus Celebrates Five-Year Anniversary of Qelbree FDA Approval, Continuing to Deliver on Real-World Experience in ADHD (GlobeNewswire)
May-27-26 04:30PM	Supernus Pharmaceuticals to Participate in June Investor Conferences (GlobeNewswire)
May-06-26 05:00PM	Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference (GlobeNewswire)
May-05-26 04:42PM	Supernus: Q1 Earnings Snapshot (Associated Press)
04:05PM	Loading…
04:05PM	Supernus Announces First Quarter 2026 Financial Results (GlobeNewswire)
Apr-22-26 04:15PM	Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026 (GlobeNewswire)
Apr-20-26 05:00PM	Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig (Business Wire)
Feb-25-26 01:07AM	Supernus Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
12:03AM	Supernus Pharmaceuticals Inc (SUPN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-24-26 10:30PM	Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
09:55PM	Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
05:08PM	Supernus: Q4 Earnings Snapshot (Associated Press Finance)
04:21PM	Supernus Pharmaceuticals's (NASDAQ:SUPN) Q4 CY2025: Strong Sales (StockStory)
04:05PM	Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-23-26 06:15PM	Supernus Pharmaceuticals to Participate in March Investor Conferences (GlobeNewswire)
Feb-22-26 10:08PM	Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-17-26 10:00AM	Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline (Zacks)
Feb-16-26 11:04PM	3 Reasons to Avoid SUPN and 1 Stock to Buy Instead (StockStory)
Feb-12-26 04:35PM	Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026 (GlobeNewswire)
Feb-06-26 11:30AM	BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View (Zacks)
Feb-03-26 07:56AM	New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings (Zacks)
Dec-19-25 06:57AM	Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3 (Insider Monkey)
Dec-03-25 04:05PM	Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference (GlobeNewswire)
Nov-21-25 04:06PM	Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
11:00AM	Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) (StockStory)
Nov-12-25 04:05PM	Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-11-25 12:36AM	5 Must-Read Analyst Questions From Supernus Pharmaceuticals's Q3 Earnings Call (StockStory)
Nov-06-25 08:07AM	Supernus Pharmaceuticals (SUPN) is Benefiting from Its Strength in Financial Position (Insider Monkey)
Nov-05-25 12:26PM	Why Supernus Pharmaceuticals (SUPN) Shares Are Trading Lower Today (StockStory)
08:37AM	SUPN Q3 Deep Dive: Growth Drivers Offset By Supply Constraints and Integration Costs (StockStory)
12:03AM	Supernus Pharmaceuticals Inc (SUPN) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst ... (GuruFocus.com)
Nov-04-25 08:30PM	Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:20PM	Supernus Pharmaceuticals (SUPN) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:18PM	Supernus: Q3 Earnings Snapshot (Associated Press Finance)
04:12PM	Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Strong Q3 (StockStory)
04:01PM	Supernus Announces Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-02-25 10:01PM	Supernus Pharmaceuticals (SUPN) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-30-25 02:02PM	BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View (Zacks) +15.41%
10:00AM	Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-29-25 05:15PM	BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
12:00PM	Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy (Zacks)
09:35AM	Skyworks upgraded, UnitedHealth downgraded: Wall Street's top analyst calls (The Fly)
Oct-28-25 10:00AM	Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline (Zacks)
09:14AM	BridgeBio Pharma (BBIO) Soars 17.1%: Is Further Upside Left in the Stock? (Zacks)
Oct-27-25 09:15AM	Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-24-25 10:33AM	Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key (Zacks)
Oct-22-25 12:10PM	Why Supernus (SUPN) is Poised to Beat Earnings Estimates Again (Zacks)
Oct-21-25 05:00PM	Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 (GlobeNewswire)
Oct-16-25 03:23AM	Zacks.com featured highlights include United Natural Foods, Teladoc Health, Supernus and BRP (Zacks)
Oct-15-25 03:08PM	Can 4 Relative Price Strength Stocks Defy Market Swings? (Zacks)
Oct-13-25 12:00PM	Supernus Pharmaceuticals (SUPN) Is Up 2.81% in One Week: What You Should Know (Zacks)
Oct-12-25 11:31PM	Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines (StockStory)
Oct-10-25 11:55AM	Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines? (Zacks)
09:15AM	Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? (Zacks)
Oct-09-25 12:05PM	Supernus Pharmaceuticals (SUPN) Stock Is Up, What You Need To Know (StockStory)
Sep-25-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Supernus Pharmaceuticals (SUPN) is a Great Choice (Zacks)
Sep-23-25 09:15AM	Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-18-25 09:17AM	Biogen Gets EU Nod for First Postpartum Depression Drug (Zacks)
Sep-16-25 12:02AM	3 Reasons to Avoid SUPN and 1 Stock to Buy Instead (StockStory)
Aug-27-25 04:15PM	Supernus Pharmaceuticals to Participate in September Investor Conferences (GlobeNewswire)
Aug-13-25 12:12AM	5 Insightful Analyst Questions From Supernus Pharmaceuticals's Q2 Earnings Call (StockStory)
Aug-12-25 11:43PM	SUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade (StockStory)
Aug-11-25 08:00AM	Here's Third Avenue Small-Cap Value Fund's Update on Supernus Pharmaceuticals (SUPN) (Insider Monkey)
Aug-07-25 02:00PM	Supernus Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Aug-06-25 01:20PM	Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today (StockStory)
03:27AM	Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... (GuruFocus.com)
Aug-05-25 08:30PM	Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:35PM	Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
06:18PM	Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales (StockStory)
05:32PM	Supernus: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Supernus Announces Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-03-25 11:08PM	Supernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect (StockStory)
Aug-01-25 07:09AM	Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics (Pharmaceutical Technology)
Jul-31-25 10:48AM	Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up (Zacks) +16.09%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Khattar Jack A.	President, CEO	Aug 12 '26	Option Exercise	0.00	29,849	0	1,270,993	Aug 14 05:12 PM
Rubin Jonathan	SVP, Chief Medical Officer	Aug 12 '26	Option Exercise	0.00	750	0	14,342	Aug 14 05:11 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Aug 12 '26	Option Exercise	0.00	2,500	0	19,795	Aug 14 05:11 PM
Mottola Frank	SVP, Chief Tech. Ops. Officer	Aug 12 '26	Option Exercise	0.00	1,650	0	20,341	Aug 14 05:10 PM
DEC TIMOTHY C	Senior Vice-President & CFO	Aug 12 '26	Option Exercise	0.00	1,250	0	9,733	Aug 14 05:09 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 17 '26	Option Exercise	38.51	50,000	1,925,537	67,044	Mar 18 05:18 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 16 '26	Option Exercise	33.62	50,000	1,681,205	67,044	Mar 18 05:18 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 18 '26	Option Exercise	39.40	7,250	285,650	24,294	Mar 18 05:18 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 17 '26	Sale	50.30	50,000	2,514,886	17,044	Mar 18 05:18 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 16 '26	Sale	50.28	50,000	2,513,925	17,044	Mar 18 05:18 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 18 '26	Sale	49.60	7,250	359,621	17,044	Mar 18 05:18 PM
PADMANABH P BHATT	Officer	Mar 17 '26	Proposed Sale	50.21	57,250	2,874,522		Mar 17 04:29 PM
PADMANABH P BHATT	Officer	Mar 16 '26	Proposed Sale	49.91	50,000	2,495,500		Mar 16 04:38 PM
Khattar Jack A.	President, CEO	Mar 13 '26	Sale	50.37	35,000	1,763,124	958,100	Mar 16 04:08 PM
Hudson Frederick M.	Director	Mar 12 '26	Sale	50.61	5,369	271,725	60,413	Mar 16 04:07 PM
THE KBT TRUST U/A DTD 12/30/20	Director	Mar 13 '26	Proposed Sale	50.46	35,000	1,766,100		Mar 13 04:22 PM
FREDERICK M HUDSON	Director	Mar 12 '26	Proposed Sale	50.62	5,369	271,752		Mar 12 04:06 PM
WILLIAM TODD HORICH	Officer	Mar 10 '26	Proposed Sale	55.00	4,439	244,145		Mar 10 04:18 PM
Khattar Jack A.	President, CEO	Mar 06 '26	Option Exercise	0.00	38,640	0	1,245,218	Mar 10 04:13 PM
Mottola Frank	SVP, Chief Tech. Ops. Officer	Mar 06 '26	Option Exercise	0.00	3,750	0	21,856	Mar 10 04:13 PM
Mottola Frank	SVP, Chief Tech. Ops. Officer	Mar 09 '26	Sale	53.65	1,623	87,074	18,440	Mar 10 04:13 PM
DEC TIMOTHY C	Senior Vice-President & CFO	Mar 06 '26	Option Exercise	0.00	6,000	0	9,682	Mar 10 04:12 PM
Horich William Todd	SVP, Commercial Operations	Mar 06 '26	Option Exercise	0.00	7,500	0	9,991	Mar 10 04:12 PM
Horich William Todd	SVP, Commercial Operations	Mar 10 '26	Sale	55.00	4,439	244,145	0	Mar 10 04:12 PM
Horich William Todd	SVP, Commercial Operations	Mar 09 '26	Sale	54.00	4,438	239,652	4,439	Mar 10 04:12 PM
WILLIAM TODD HORICH	Officer	Mar 09 '26	Proposed Sale	54.00	4,438	239,652		Mar 09 04:43 PM
FRANK MOTTOLA	Officer	Mar 09 '26	Proposed Sale	53.65	1,623	87,074		Mar 09 04:16 PM
GEMAYEL GEORGES	Director	Mar 06 '26	Option Exercise	25.30	7,905	199,996	36,064	Mar 09 04:06 PM
GEMAYEL GEORGES	Director	Mar 05 '26	Sale	53.71	10,000	537,100	28,159	Mar 09 04:06 PM
GEMAYEL GEORGES	Director	Mar 06 '26	Sale	53.00	8,787	465,711	27,277	Mar 09 04:06 PM
GEORGES GEMAYEL	Director	Mar 06 '26	Proposed Sale	53.01	8,787	465,771		Mar 06 04:24 PM
GEORGES GEMAYEL	Director	Mar 05 '26	Proposed Sale	53.71	10,000	537,117		Mar 05 04:04 PM
GEMAYEL GEORGES	Director	Feb 23 '26	Option Exercise	12.98	15,000	194,700	33,684	Feb 25 04:36 PM
Sensenig Bethany	Director	Feb 19 '26	Option Exercise	0.00	4,475	0	4,475	Feb 23 04:39 PM
Sensenig Bethany	Director	Feb 19 '26	Sale	51.01	4,475	228,265	0	Feb 23 04:39 PM
BETHANY SENSENIG	Director	Feb 19 '26	Proposed Sale	50.20	4,475	224,645		Feb 19 04:22 PM
Hudson Frederick M.	Director	Jan 09 '26	Option Exercise	12.98	15,000	194,700	61,307	Jan 12 04:09 PM
Mottola Frank	SVP, Chief Tech. Ops. Officer	Dec 19 '25	Option Exercise	28.82	20,000	576,500	30,496	Dec 22 04:04 PM
Mottola Frank	SVP, Chief Tech. Ops. Officer	Dec 19 '25	Sale	50.41	20,000	1,008,150	15,496	Dec 22 04:04 PM
FRANK MOTTOLA	Officer	Dec 19 '25	Proposed Sale	49.28	20,000	985,600		Dec 19 04:23 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Dec 18 '25	Option Exercise	0.00	1,500	0	15,218	Dec 19 04:05 PM
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Dec 18 '25	Sale	44.44	710	31,552	14,508	Dec 19 04:05 PM
NEWHALL CHARLES W III	Director	Nov 21 '25	Option Exercise	12.98	15,000	194,700	119,644	Nov 24 06:16 PM

Supernus, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of treatments for patients living with central nervous system (CNS) diseases. Its portfolio includes treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company was founded in 2005 and is headquartered in Rockville, MD.

MBAJack A. Khattar

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Supernus Inc

Upgrade your Finviz experience